Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
Portfolio Pulse from Benzinga Insights
Travere Therapeutics (NASDAQ:TVTX) has received diverse analyst ratings over the past three months, with a majority being bullish. Analysts have set a 12-month average price target of $22.17, up from $18.09. The company has shown significant revenue growth but faces challenges with high debt and low returns on equity and assets.
October 21, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics has received predominantly bullish analyst ratings, with a significant increase in the average price target to $22.17. The company shows strong revenue growth but faces financial challenges with high debt and low returns on equity and assets.
The majority of analysts have given bullish ratings, and the average price target has increased significantly, indicating positive sentiment. However, the company's financial metrics such as high debt and low ROE/ROA suggest underlying challenges. The overall impact is likely positive due to the bullish sentiment and increased price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100